**Name of journal: World Journal of Stem Cells**

**ESPS Manuscript NO: 12794**

**Columns: Minireviews**

**Renal stem cell reprogramming: Prospects in regenerative medicine**

Morales EE *et al*. Renal cell reprogramming

Elvin E Morales, Rebecca A Wingert

**Elvin E Morales, Rebecca A Wingert,** Department of Biological Sciences and Center for Zebrafish Research, University of Notre Dame, Notre Dame, IN 46556, United States

**Author contributions:** Morales EE and Wingert RA both designed the content of the manuscript, drafted and revised the manuscript, and approved the final version for publication.

**Supported by** National Institutes of Health, No. DP2 OD008470, R01 DK100237; Start-up funds from the University of Notre Dame and College of Science; and a generous donation for stem cell research to the University of Notre Dame by Elizabeth and Michael Gallagher on behalf of the Gallagher family

**Correspondence to: Rebecca A Wingert, PhD,** Department of Biological Sciences and Center for Zebrafish Research, University of Notre Dame, 100 Galvin Life Sciences, Notre Dame, IN 46556, United States. rwingert@nd.edu

**Telephone:** +1-574-6310907 **Fax:** +1-574-6317413

**Received:** July 26, 2014 **Revised:** August 21, 2014

**Accepted:** August 30, 2014

**Published online:**

**Abstract**

Stem cell therapy is a promising future enterprise for renal replacement in patients with acute and chronic kidney disease, conditions which affect millions worldwide and currently require patients to undergo lifelong medical treatments through dialysis and/or organ transplant. Reprogramming differentiated renal cells harvested from the patient back into a pluripotent state would decrease the risk of tissue rejection and provide a virtually unlimited supply of cells for regenerative medicine treatments, making it an exciting area of current research in nephrology. Among the major hurdles that need to be overcome before stem cell therapy for the kidney can be applied in a clinical setting are ensuring the fidelity and relative safety of the reprogrammed cells, as well as achieving feasible efficiency in the reprogramming processes that are utilized. Further, improved knowledge about the genetic control of renal lineage development is vital to identifying predictable and efficient reprogramming approaches, such as the expression of key modulators or the regulation of gene activity through small molecule mimetics. Here, we discuss several recent advances in induced pluripotent stem cell technologies. We also explore strategies that have been successful in renal progenitor generation, and explore what these methods might mean for the development of cell-based regenerative therapies for kidney disease.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Kidney; Regeneration; Induced pluripotent stem cell; Reprogramming; Differentiation; Stem cell; Renal progenitor

**Core tip:** The identification of regenerative therapies to treat kidney disease is an exciting but challenging area of ongoing scientific investigation. Cellular reprogramming may provide a tractable means to replace damaged renal tissue, and current researchers have pursued a number of innovative ways to produce renal cell types. Here we explore the issues confronting several reprogramming technologies, recent advances in reprogramming renal cells, and discuss areas of future scrutiny that are needed to help develop cell-based therapies for various kidney disease conditions.

Morales EE, Wingert RA. Renal stem cell reprogramming: Prospects in regenerative medicine. *World J Stem Cells* 2014; In press

**INTRODUCTION: KIDNEY DISEASES AND THE NOTION OF THERAPEUTIC USES OF INDUCED PLURIPOTENT CELLS FOR RENAL REPLACEMENT THERAPY**

Kidney organs perform essential physiological roles in excretion and homeostasis[1]. Kidney diseases can arise during development, juvenile, or adult life. Types of renal disease include acute kidney injury (AKI), which is the abrupt loss of renal function that can often become permanent, and chronic kidney disease (CKD), the progressive loss of renal function that culminates in organ failure known as end stage renal disease (ESRD)[1,2]. The need for new treatments for kidney disease, the 8th leading cause of death in the United States[3], is a growing concern in the medical field. For example, there are approximately 31 million people in the United States diagnosed with CKD[4]. Unfortunately, kidney diseases are a global health problem as well, and have continued to increase in incidence in correlation with the rise in aged populations and escalation in conditions like diabetes that often negatively impact renal health[5-8]. At present, kidney disease treatments deal with symptom management through the renal replacement therapies of dialysis or organ transplant. However, formulating therapies that repair kidney structure and restore compromised functionality is of the upmost importance considering the limited numbers of viable kidneys available for transplant, as well as the complications that can arise in organ recipients[9-13]. To identify innovative ways to combat kidney diseases, numerous research groups have focused their energies on the identification of adult renal stem cells[14-17]. However, this has remained a controversial topic despite the multitude of studies performed to date[14-17]. In addition to the search for endogenous renal stem cells, the study of renal lineage specification during kidney organogenesis has been pursued-knowledge which can be applied toward the development of cell-based therapies for the purpose of kidney regeneration that would not necessitate the employment of adult stem cells.

One such cell-based alternative is the use of induced pluripotent stem cells (iPS) derived from the patient’s own tissue. iPS cells can be used to study development and cell differentiation without the need for embryonic stem (ES) cell lines, whose cell source carries with it a surplus of ethical concerns, and can provide a resource to help researchers with disease modeling and drug development[9]. Using iPS cells from the patient’s renal tissue can serve to circumvent the need for a kidney transplant and avoid the use of lifelong immunosuppressant drug treatments. Thus, the notion of iPS-based regenerative medicine has many appealing benefits if the paramount challenges associated with realization of such cell-based therapies can be overcome. Utilizing integrating viral vectors containing the “Yamanaka factors” to reprogram cells has shown substantial success in generating iPS cells (approximately 0.1%), but the fact that these viral vectors integrate into the genome (sometimes in large copy number) has been a serious cause for debate as to their toxicity and their relative capability to be used in a clinical setting. Researchers have also investigated other avenues such as the use of non-integrating vectors so as to make the iPS cells safer to use in cell therapies, but with limited success, as evidenced by the very low induction rates and relative efficiency of the reprogramming method (approximately 0.001%). Making safer and more controllable iPS cells is an integral part of developing cell-based therapies for the treatment of diseases and injuries. For example, Abad *et al*[18] shows evidence of how uncontrolled reprogramming can affect the body in the form of teratomas developing in multiple organs of transgenic mice transiently expressing the four “Yamanaka factors”. Other alternatives to the use of reprogramming factors are also being investigated, such as the use of microRNAs (miRNAs) to generate iPS cells. This method shows much promise, even though the cells’ behavior *in vivo* still has to be controlled (approximately 10% efficiency reported in previous studies)[19].

For the purposes of treating kidney disease, researchers have been assessing different ways of obtaining renal progenitor cells, and one such way involves partial reprogramming of differentiated renal cells into a renal progenitor state. Experimental evidence has supported the notion that the more closely related the start and end cells types are, the more efficient the reprogramming process will be. Although the method proved to be better than most at producing reprogrammed cells (approximately 0.875%)[20], the overall amount of progenitors produced is still not cost-effective enough to be of applicable merit for therapeutic purposes. Another drawback to this partial reprogramming method is the thorough screening process that has to be applied in order to find the adequate combination of genes that will successfully reprogram the kidney cells into a progenitor-like state, which would be both time-consuming and costly. A method of obtaining renal progenitors that has received significant attention is the directed differentiation of iPS cells. Typically done with growth factors (which are rather expensive), exciting recent reports have now suggested that certain low-cost chemical compounds can be used to achieve the same goal of directing iPS cells towards a specific renal cell lineage with an approximate 90% conversion rate in one week. Although still dependent on the production of iPS cells, directed differentiation into renal progenitors is still a promising method that can be applied in tandem with a more optimized, efficient, and safer reprogramming protocols. In the following sections we further discuss these and other recent advances, as well as their general impact in the medical field.

**REPROGRAMMING METHODS: REVERSE ENGINEERING TO OBTAIN STEM AND OTHER PROGENITOR CELLS FROM DIFFERENTIATED CELLS**

Current therapies directed towards the treatment of kidney disease focus on symptom management instead of treating and hopefully curing the overall condition, and because of these researchers are working on alternatives that may now aid in the restoration of normal kidney function. As aforementioned, one alternative to current methods is the use of reprogrammed cell-based therapies in order to restore damaged or diseased kidneys. Two of the most prominent reprogramming strategies currently being used involve either the conversion of different sources of stem cells into renal progenitors, or the reprogramming of differentiated renal cell populations into a more pluripotent state (Figure 1).

Traditional cell reprogramming involves the overexpression of developmental genes in differentiated adult cells in order to induce an earlier developmental and pluripotent phenotype. The typical factors that are overexpressed for cell reprogramming, discovered by Takahashi and Yamanaka back in 2006[21,22], are OCT4, SOX2, c-MYC, and KLF4 (now deemed “Yamanaka factors”), these factors are typically transfected into cells through the use of lentiviral vectors, which insert these exogenous genes into the host genome. At first, a cocktail of four viral vectors, each one containing one of the previously mentioned “Yamanaka factors” was introduced into the cell in order to promote a change in cell phenotype, this however, these techniques lacked efficiency due to many non-specific genomic integrations, as well as the heterogeneous population that resulted from the process (some cells were only partially reprogrammed because not all of the vectors integrated)[21,22]. In terms of kidney disease, producing iPS cells from cells of renal origin would contribute greatly to the development of cell therapies and treatments as they would be predicted to integrate more readily into the diseased kidney due to their conserved epigenetic memory[23].

Interestingly, Zhou *et al*[24,25] were able to generate iPS cells from human exfoliated renal epithelial cells found in urine, something that can be collected without the need for surgical intervention, which would help in the development of therapies for kidney disease due to their epigenetic memory of renal origin. Using a cocktail of four different retroviruses containing the four “Yamanaka factors” they were able to create iPS cells (in about 16-25 d after transduction) from the previously mentioned cell source (cultured for about a week from 13 different test subjects, which means that the complete protocol would last about a month to produce iPS cells) with varying degrees of reprogramming efficiency (0.01%-4.0%) and ability to differentiate, something that is to be expected when you use multiple integration vectors, mainly because the researcher cannot assess if the cells have incorporated all of the four reprogramming factors, or if the integrated vector copy number is low enough for the reprogrammed cells to be viable for therapeutic purposes (something that was not investigated in this study). Although a reprogramming efficiency of 4.0% is relatively high compared to other studies, the fact that there is great variation between the iPS cells produced (evidenced by the varying degrees of reprogramming efficiencies between the different donors, and that not a lot of the iPS cells produced could differentiate into other cells types) greatly diminishes their clinical applications, and provides further evidence that utilizing multiple integration vectors to reprogram cells is not an effective method for producing iPS cells for therapeutic purposes.

Researchers have tried to address this issue by trying create a better method of reprogramming that could decrease the number of genomic integrations, and assure that all of the factors necessary for reprogramming are being expressed within the cell. Sommer *et al*[26] managed to do just this by creating a single lentiviral vector containing all of the “Yamanaka factors” which is able to convert mouse postnatal fibroblasts into iPS cells. Not only were they able to ensure that all four transcription factors were integrated into the cell’s genome, but they were able to reduce the amount of genomic integrations to a mean of about 1.5-2.8 proviral copies[26]. Compared to the multiple vector approach, this single vector method has an increased efficiency of 0.5%, which is about 50 times more efficient (relative efficiency of the multiple vector method is about 0.01%-0.05%), but this number might vary between cell types due to the many unique properties found in the various tissues throughout the body. Fortunately iPS cells have already been created from cell sources from cells of distinct embryonic origins (endoderm, mesoderm, ectoderm). This will benefit the development of regeneration cell therapies as iPS cells derived from the affected or injured organ will work more effectively in cell therapies that intend to regenerate the particular organ of interest, because of the genome-wide epigenetic memory of the differentiated adult cell that is to be reprogrammed [27].

Working under the previously stated premise (specifically in the case of renal disease), Wang *et al*[23] were able to generate iPS cells from mouse renal tubular epithelial cells (RTECs) using a single lentiviral vector containing the previously mentioned “Yamanaka factors” in about 21 d. The cells produced in this study were relatively indistinguishable from mouse ES cells, as confirmed by morphological, immunocytochemical, genetic expression, and karyotype analysis[23]. Not only did these cells adopt an ES-like morphology and were able to express undifferentiated ES cell markers such as fibroblast growth factor 4 (FGF-4) and NANOG, but they were also able to differentiate into cell types of all three germ layers, as evidenced by the presence of AFP, desmin, and nestin (endoderm, mesoderm, and ectoderm markers respectively) in embryoid bodies formed from said cells[23]. The cells also exhibited a normal 40XY karyotype and once reprogrammed, the viral transgenes were largely silenced which is necessary if there is any chance of applying this method in clinical applications, mainly to avoid problems during differentiation that might result in tumor development; the relative efficiency of this method, however, leaves something to be desired (0.1%)[23].

Another reprogramming strategy that researchers have pursued is partial reprogramming of cells into a more multipotent phenotype that can produce cell lineages of a specific organ structure, which in the case of Hendry *et al*[20] would be embryonic nephron progenitors (NPs). The efficiency of the reprogramming process is correlated to the lineage relationship between the start and end cell types, in other words, the more closely related the start and end cells types are, the more efficient the reprogramming process[20]. Hendry and colleagues investigated this premise by trying to generate NPs from HK2 cells line (human kidney cell line; adult proximal tubule cells)[20]. Through combinatorial screening of 15 different transcription factors associated with the specification of the nephron progenitor phenotype they were able to identify 6 (*SIX1, SIX2, OSR1, EYA1, HOAXA11, SNAI2*) genes that would recapitulate the network of genes associated with the cap mesenchyme (CM)[20]. Each factor was packed into individual lentiviral constructs accompanied by green fluorescent protein (GFP) to identify successfully infected cells, and successful reprogramming events were defined by significant morphological changes as well as robust expression of SIX2 and Cbp/P300-interactin transactivator 1 (CITED1) protein, CM-specific markers[20]. Reprogrammed cells showed upregulation of *Matrix metalloproteinase 9* and *2* (*MMP9* and *MMP2*), epithelial-to-mesenchymal transition (EMT) markers, as well as repressed expression of epithelial cadherin (*E-CADHERIN*), which suggests the occurrence of an EMT event within these cells[20].

Further evidence of the cells’ conversion into nephron progenitors can be seen in a recombination assay that was developed to test the induced NPs’ potential in *ex vivo* organoid cultures[28,29]. They found that the induced progenitors were able to integrate with the endogenous NP field, and failed to integrate into the uretic bud compartments (a cellular population that the CM does not make). The overall efficiency of this partial reprogramming process is about 0.875%, which is substantially better than many of the techniques discussed so far (most likely due to the close relation between adult proximal tubule cells and NPs), however, the use of multiple lentiviral constructs makes the use of these cells quite toxic; therefore integrating all of these factors into a single construct might increase the efficiency of the reprogramming quite drastically, as well as their potential for use in therapies.

**TANGENTIAL AND NON-INTEGRATION METHODS OF REPROGRAMMING**

The use of integrating viral vectors has become quite widespread in the field of cell reprogramming, but because of various concerns that have arisen during their use (interruption of the cell’s genome and/or the risk spontaneous reactivation of the viral genome that might lead to tumor formation) researchers are actively looking for different alternatives so as to decrease the risk of using reprogrammed cells in the treatments of diseases such as end-stage renal disease (ESRD). Nightingale et al. (2006) were able to produce a non-integrating lentiviral vector that was able to transiently express GFP in about 90% of cultured human T lymphoid cells for approximately 20 d, which speaks to the potential of non-integrating vectors[30]. In 2008, Stadtfeld *et al*[31] were able to generate mouse iPS cells from fibroblasts and liver cells by using non-integrating adenoviruses that transiently expressed the four “Yamanaka factors”. The cells were showed distinct characteristics of pluripotency such as the expression of endogenous pluripotency genes, demethylation of *Oct4* and *Nanog* promoters, and the ability to produce teratomas *in vivo* and contribute to all three germ layers[31]. Even though the infection efficiency of the adenoviral vectors was relatively high (50%-60% for quadruple infected cells), the overall reprogramming efficiency this non-integrating method was between 0.0001% to 0.001% (significantly lower than integrating viral methods; 0.1% on average)[31], something that is probably due to the rapid dilution of the adenoviruses during cell division which results in the cells not being exposed to the reprogramming factors for an adequate amount of time so as to induce a successful change in phenotype.

Another example of iPS cells created by non-integrating vectors can be seen in Yu *et al*[32]. Yu and colleagues were able to create human iPS cells by utilizing three modified episomal vectors containing different combinations of six reprogramming factors (*OCT4, SOX2, NANAOG, LIN28, c-MYC,* and *KLF4*) and the SV40 large T gene (*SV40LT*)to counteract the toxic effects of *c-MYC* expression, a cis-acting oriP element and an Epstein-Barr nuclear antigen 1 (EBNA1) gene[32]. The latter of these elements provided the vector with the ability to be transfected without the need for viral packaging and to be stably replicated outside of the chromosome[32]. The factors packaged inside the vectors were linked by the internal ribosome entry site 2 (IRES2), and this was done in order to increase reprogramming efficiency by coexpressing them[32]. Utilizing these vectors researchers were able to make iPS cells that exhibited typical ES cell colony morphology and gene expression profile, and they were able to produce teratomas *in vivo* that contained differentiated derivatives of all three germ layers[32]. Subclones of the reprogrammed cells showed no signs of the vector or transgene sequences other than the change in phenotype, which is an incredible accomplishment, the reprogramming efficiency of the method however, is rather low (about three to six colonies per 106 input cells)[32].

Although non-integrating vectors are a good alternative in order to produce safer iPS cells for use in treatments, they are not very cost-efficient considering that these methods and vectors produce very low amounts of reprogrammed cells. Another alternate method that has seen a lot of attention in recent years is the use of miRNAs instead of exogenous transcription factors as a means of reprogramming[19]. Wang *et al*[19] used a lentiviral vector containing *miR302/367*, a unique cluster of miRNAs that is highly expressed in EM cells, in order to produce iPS cells from human embryonic kidney (HEK) 293T cells and found that these reprogrammed cells generated ES-like colonies, showed increased expression of ES cell markers (Sox2, Klf4, c-Myc, OCT4, LIN28 and Nanog), could form embryoid bodies, and could differentiate into germ-like cells *in vitro* and *in vivo*. So as to improve the differentiation potential of the miRNA-induced iPS cells researchers cultured the HEK293T cells in serum-free media, as well as in the presence of two small molecules: vitamin C and fibroblast growth factor (bFGF) so as to better shape the morphology of the reprogrammed cells[19]. Although the overall efficiency of the reprogramming method described is yet to be determined, previous reprogramming studies with miRNAs have demonstrated this type of approach to be more efficient than the standard reprogramming factor methods (10% *vs* 0.1%, respectively)[33], making this type of method a promising candidate for further studies.

**FORWARD THINKING: OBTAINING RENAL PROGENITORS USING LOW-COST AND EFFICACIOUS SMALL MOLECULES**

In the endeavor to create renal progenitors, controlled differentiation of iPS cells has become a good alternative to partial reprogramming of differentiated cells. One particular technique that stands out is the use of small molecules in order to induce a more renal-specific pluripotent state. Lam *et al*[34] created an intermediate mesoderm (IM)-specific differentiation platform around the small molecule CHIR99021, a glycogen synthase kinase-3β inhibitor (CHIR). This inhibitor manages to recapitulate mesendoderm formation during development in human pluripotent stem cells (hPSCs), as evidenced by the compounds ability to produce cell lineages that transiently expressed various primitive streak genes such as *BRACHY*, *MIXL1*, *FOXA2*, *EOMES*, and *GSC*[34]. The transient expression pattern of these genes in the CHIR-treated cells during a 72 h period is also consistent with that found in cells during the course of gastrulation, which means that CHIR99021 imitates normal developmental mimetics[34].

Utilizing this compound researchers were able to screen various exogenous factors in order to determine the minimum requirements needed promote differentiation of these CHIR-induced mesendoderm–like cells toward IM[34]. They reported that fibroblast growth factor-2 (FGF2) in combination with retinoic acid (RA) was able to induce IM differentiation in the mesendoderm-like cells. This conclusion was drawn from the fact that the treated cells were both *PAX2* and *LHX1* positive, two markers for which coexpression in the same domain has only been described in the developing kidney and dorsal spinal cord. Further evidence that these *PAX2*+*LHX1*+ cells were directed to an IM state and that they could produce IM-derived cell populations and tissues came in the form of tubule structures (with primary cilia) expressing proximal tubular markers once the exogenous FGF2 and RA were removed from the culture media. One of the many differentiated kidney markers whose expression was evaluated in the *PAX2*+*LHX1*+ cells was *SIX2*, a multipotent nephron progenitor cell marker. This nephron progenitor population composes what is known as the CM and these give rise to nearly all epithelial cell types in the nephron tubule, with the exception of those from the collecting duct. Lam and colleagues were able to use the double positive IM-like cells in order to screen different growth factors so as to identify the conditions that promote and sustain a *SIX2*+ cell population, and they were able to determine that the addition of FGF9 and Activin A could do just this, as well as induce the expression of other CM markers such as *SALL1* and *WT1*. Although researchers were able to effectively produce IM-like cells that are able to differentiate into subsequent renal cell populations, the need for exogenous growth factors is still an issue due to that fact that these very same growth factors are incredibly expensive, and therefore not very cost-effective to use in clinical applications.

Araoka *et al*[35] on the other hand, utilized a combination consisting of only small molecules, as opposed to small molecules and growth factors, in order reach the same goal. In this particular strategy the mesendoderm stage is skipped altogether and the hPSCs are differentiated directly into an IM state. Using high throughput chemical screening they were able to identify two compounds that increased induction of *Odd-skipped related 1* (*Osr1*), a transcriptional regulator that is expressed in the embryonic day 7.5 IM till kidney organogenesis and therefore a good marker to utilize in order to identify IM cells. The two compounds identified were AM580 and TTNPB, RA receptor antagonists (RAR) that induce differentiation of hPSCs into OSR1+ IM cells with relatively high efficiency (> 60% and > 50% respectively) when compared to positive controls. To further optimize OSR1 induction researchers combined each RAR with CHIR, which resulted in an increased induction rate of around 80% in only 5 d utilizing only two chemicals in a serum –free environment.

As mentioned before, one of the main differences between the methods used Araoka *et al*[35] and Lam *et al*[34] is that the former can skip the mesendoderm stage altogether. This was demonstrated when researchers analyzed mesendoderm markers (*BRACHYURY, GOOSECOID,* and *MIXL1*) in the small molecule-treated hPSCs, and found that the induction rate for BRACHYURY+ cells was around 6%, and that expression levels for said markers were very low in cells produced from the small molecule method when compared to cells produced with CHIR and growth factor activin A. The ability of these IM-like cells to produce the various IM-derivative cell types was also evaluated, and after additional days of differentiation researchers found that these induced IM cells did in fact produce cells expressing marker genes for various IM-derivative cell types such as *FOXD1, SALL4, GATA4,* among others. These cells also had the ability to give rise to the derivative cell types *in vivo*, as well as renal tubule-like structures positive for renal tubule markers such as *Lotus tetragonolobus* lectin(LTL), E-CADHERIN, and laminin *in vitro*.

Both of these studies[34,35] provide evidence that utilizing small molecules in order to produce renal progenitors for cell therapies is a viable option in the field of regenerative medicine, and the various benefits that this type of method provides makes it a good alternative to explore. Utilizing these chemical compounds is not only less costly, but more efficient in terms of number of cells converted to the desired phenotype (even though the reprogramming efficiencies for the template iPS cells were not stated in either one of the studies). Unfortunately there is still some variability between studies that needs to be addressed before any progress can be made on any viable therapeutic solution.

Both of the methods described above are highly efficient for IM differentiation of hPSCs in terms of the time the procedure takes, the markers analyzed, and the compounds used[34,35]. Lam *et al*[34] utilizes a method that has both chemical compounds and growth factors, but only takes 3 d to produce IM cells. Araoka *et al*[35] on the other hand only use chemical compounds, but take about two more days in order to reach the same goal. In terms of markers utilized the former uses a combination of LHX1 and PAX2 (a pair of markers that, as stated previously, are only found in the developing kidney and dorsal spinal cord), while the latter uses an engineered *OSR1-GFP* human iPS cell line to verify if the cells have reached an IM state, a gene that is also expressed in the lateral plate mesoderm and can therefore provide some heterogeneity to the sample that might alter the results of future studies.

**CONCLUSION**

Recent progress in knowledge about cellular reprogramming has rapidly advanced prospects for the development of regenerative therapies for the medical treatment of many conditions, among them being kidney diseases, making this a very exciting time in the field of nephrology. Here, we discussed a number of research studies in the field of stem cell reprogramming. We explored how such methods have been utilized to reprogram renal lineages, and thus might be used to develop therapies to treat kidney disease. Additionally, iPS cells can be used for disease modeling to identify targeted therapeutics for heritable conditions[36]. Moving forward, there are a number of complex issues to further resolve about the therapeutic application of iPS cells for disease treatment, and most assuredly other issues yet to be identified, which apply both to the kidney and other organs within the body (Figure 2).

Issues involved in the therapeutic application of reprogrammed cells include the number and type of cells needed, along with the identification of an appropriate delivery system for the condition to be treated. Currently, there are various ongoing clinical trials in the United States that are using stem cells to treat a wide range of conditions such as age-related macular degenerations to polycystic kidney disease[37]. The amount of cells utilized by these studies can fluctuate between the stem cells type and the way they are used (50000-200000 human embryonic stem cells in retinal cell transplants and 2 × 106 mesenchymal stem cells (MSCs)/kg of patient’s weight in kidney disease treatments[37,38]), but even so the amount of pluripotent cells produced by the methods mentioned in this review are still relatively low when compared to the amount used in the before-mentioned trial therapies.

Other issues that still need to be addressed are cell quality (can you isolate healthy renal cells to reprogram as opposed to the diseased ones?) and downstream processing, a problem because, due to ethical reasons, many of the pluripotency tests that are usually performed on reprogrammed cells can’t be done with human iPS cells, which might create some heterogeneity within the human iPS cell lines. Also, we have barely scratched the surface of how epigenetic memory affects iPS cell differentiation patterns. All of these concerns still need to be investigated before adequate therapies can be developed (Figure 2).

Although there remains a sizable amount of work to be done in order to optimize the efficiency of these methods, they still represent a promising alternative to current therapies, mainly because they have the potential to provide the affected patient with the means to regain kidney function without the need for kidney transplants or dialysis. It would be interesting to see how these methods would be affected if they were done with other animal models, such as in the zebrafish, an organism that has the capacity to regenerate renal tissue[39-41], and what type of information can the differences between models reveal about how these reprogramming methods can be optimized or the nature of renal progenitors[42]. As more insights continue to be gathered about the genetic mechanisms of renal lineage development and regeneration in various vertebrate models, as represented for example by recent reports in the zebrafish[43-45], frog[46], and mouse[47], crucial information may be elucidated about potent methods to regulate renal reprogramming or even to promote pathways of endogenous cell regeneration in the damaged kidney.

Moving forward, there may be significant challenges for cell-based therapies posed by the microenvironment in the damaged kidney-termed by some as the “seed and soil” dilemma. Namely, the importance of an appropriate microenvironment, or niche, the so-called “soil”, is essential for the prosperity and normal growth of the stem cells, or “seeds”, to be administered in a putative treatment[48]. The complexity of renal anatomy and composition alone may pose significant hurdles to cell-based therapies, and can be further complicated if the environment due to the disease state is refractory to posterity of the regenerative therapy. Briefly put, altering the microenvironment to facilitate success of the cellular therapy is likely to be vital.

One promising avenue is the utilization of other stem cells, *e.g.*, MSCs, which have been shown in a number of contexts to stimulate a local, if not organismal, humoral environment that facilitates regeneration[37,38]. The kidney is in fact among such organs whose status can be improved by MSCs in some disease settings[49]. In animal models of AKI, administration of MSCs has provided renoprotective effects[50-53]. Notably, a limitation that has been recognized is the inability of MSCs to mediate improvements in chronic renal disease states[54]. These observations indicate that much remains to be learned about how to facilitate cell-based therapies with approaches that address the complex variables associated with any given disease state. Thus, it is imperative that future research is performed to better understand the relationships and physiological impacts of disease states within organisms. Nevertheless, the progress in stem cell biology to date continues to fuel enthusiasm that methods like reprogramming can be harnessed to improve quality of life and relieve suffering in the decades to come.

**ACKNOWLEDGEMENTS**

We thank the staffs of the Notre Dame Department of Biological Sciences and Office of Research for their support, and thank the Center for Zebrafish Research at Notre Dame for their outstanding dedication in the care and welfare of our zebrafish colony. Finally, we thank our research lab for their comments, discussions, and insights about this work, and our families for their constant love and support.

**REFERENCES**

1 **McCampbell KK**, Wingert RA. Renal stem cells: fact or science fiction? *Biochem J* 2012; **444**: 153-168 [PMID: 22574774 DOI: 10.1042/BJ20120176]

2 **Li Y**, Wingert RA. Regenerative medicine for the kidney: stem cell prospects & amp; challenges. *Clin Transl Med* 2013; **2**: 11 [PMID: 23688352 DOI: 10.1186/2001-1326-2-11]

3 Center for Disease Control and Prevention. “National Chronic Kidney Disease Fact Sheet: general information and national estimates on chronic kidney disease in the United States” [Internet]; 2014. Available from: http: //www.cdc.gov/diabetes/pubs/factsheets/kidney.htm

4 Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2013

5 **Bello AK**, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. *Kidney Int Suppl* 2005; **365:** S11-S17 [PMID: 16108964]

6 **Weiner DE**. Public health consequences of chronic kidney disease. *Clin Pharmacol Ther* 2009; **86**: 566-569 [PMID: 19641489 DOI: 10.1038/clpt.2009.137]

7 **Murugan R**, Kellum JA. Acute kidney injury: what's the prognosis? *Nat Rev Nephrol* 2011; **7**: 209-217 [PMID: 21343898 DOI: 10.1038/nrneph.2011.13]

8 **Venkatachalam MA**, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. *Am J Physiol Renal Physiol* 2010; **298**: F1078-F1094 [PMID: 20200097 DOI: 10.1152/ajprenal.00017.2010]

9 **Little MH**. Regrow or repair: potential regenerative therapies for the kidney. *J Am Soc Nephrol* 2006; **17**: 2390-2401 [PMID: 16870708]

10 **Sagrinati C**, Ronconi E, Lazzeri E, Lasagni L, Romagnani P. Stem-cell approaches for kidney repair: choosing the right cells. *Trends Mol Med* 2008; **14**: 277-285 [PMID: 18554984 DOI: 10.1016/j.molmed.2008.05.005]

11 **Benigni A**, Morigi M, Remuzzi G. Kidney regeneration. *Lancet* 2010; **375**: 1310-1317 [PMID: 20382327 DOI: 10.1016/S0140-6736(10)60237-1]

12 **Chhabra P**, Brayman KL. The use of stem cells in kidney disease. *Curr Opin Organ Transplant* 2009; **14**: 72-78 [PMID: 19337150 DOI: 10.1097/MOT.0b013e328320d2f5]

13 **Zubko R**, Frishman W. Stem cell therapy for the kidney? *Am J Ther* ; **16**: 247-256 [PMID: 19092639 DOI: 10.1097/MJT.0b013e3181800591]

14 **Hopkins C**, Li J, Rae F, Little MH. Stem cell options for kidney disease. *J Pathol* 2009; **217**: 265-281 [PMID: 19058290 DOI: 10.1002/path.2477]

15 **Little MH**, Bertram JF. Is there such a thing as a renal stem cell? *J Am Soc Nephrol* 2009; **20**: 2112-2117 [PMID: 19713310 DOI: 10.1681/ASN.2009010066]

16 **Guo JK**, Cantley LG. Cellular maintenance and repair of the kidney. *Annu Rev Physiol* 2010; **72**: 357-376 [PMID: 20148680 DOI: 10.1146/annurev.physiol.010908.163245]

17 **Pleniceanu O**, Harari-Steinberg O, Dekel B. Concise review: Kidney stem/progenitor cells: differentiate, sort out, or reprogram? *Stem Cells* 2010; **28**: 1649-1660 [PMID: 20652959 DOI: 10.1002/stem.486]

18 **Abad M**, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, Manzanares M, Ortega S, Serrano M. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. *Nature* 2013; **502**: 340-345 [PMID: 24025773 DOI: 10.1038/nature12586]

19 **Wang L**, Zhu H, Wu J, Li N, Hua J. Characterization of embryonic stem-like cells derived from HEK293T cells through miR302/367 expression and their potentiality to differentiate into germ-like cells. *Cytotechnology* 2013 [PMID: 24091881 DOI: 10.1007/s10616-013-9639-2]

20 **Hendry CE**, Vanslambrouck JM, Ineson J, Suhaimi N, Takasato M, Rae F, Little MH. Direct transcriptional reprogramming of adult cells to embryonic nephron progenitors. *J Am Soc Nephrol* 2013; **24**: 1424-1434 [PMID: 23766537 DOI: 10.1681/ASN.2012121143]

21 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174]

22 **Yamanaka S**, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. *Nature* 2010; **465**: 704-712 [PMID: 20535199 DOI: 10.1038/nature09229.]

23 **Wang WW**, Wang W, Jiang Y, Han GF, Lu S, Li G, Zhang J. Reprogramming of mouse renal tubular epithelial cells to induced pluripotent stem cells. *Cytotherapy* 2013; **15**: 578-585 [PMID: 23415920 DOI: 10.1016/j.jcyt.2013.01.008]

24 **Zhou T**, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of human induced pluripotent stem cells from urine samples. *Nat Protoc* 2012; **7**: 2080-2089 [PMID: 23138349 DOI: 10.1038/nprot.2012.115]

25 **Zhou T**, Benda C, Duzinger S, Huang Y, Li X, Li Y, Guo X, Cao G, Chen S, Hao L, Chan YC, Ng KM, Ho JC, Wieser M, Wu J, Redl H, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of induced pluripotent stem cells from urine. *J Am Soc Nephrol* 2011; **22**: 1221-1228 [PMID: 21636641 DOI: 10.1681/ASN.2011010106]

26 **Sommer CA**, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. *Stem Cells* 2009; **27**: 543-549 [PMID: 19096035 DOI: 10.1634/stemcells.2008-1075]

27 **Kim K**, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. Epigenetic memory in induced pluripotent stem cells. *Nature* 2010; **467**: 285-290 [PMID: 20644535 DOI: 10.1038/nature09342]

28 **Chang CH**, Davies JA. An improved method of renal tissue engineering, by combining renal dissociation and reaggregation with a low-volume culture technique, results in development of engineered kidneys complete with loops of Henle. *Nephron Exp Nephrol* 2012; **121**: e79-e85 [PMID: 23235540 DOI: 10.1159/000345514]

29 **Xinaris C**, Benedetti V, Rizzo P, Abbate M, Corna D, Azzollini N, Conti S, Unbekandt M, Davies JA, Morigi M, Benigni A, Remuzzi G. In vivo maturation of functional renal organoids formed from embryonic cell suspensions. *J Am Soc Nephrol* 2012; **23**: 1857-1868 [PMID: 23085631 DOI: 10.1681/ASN.2012050505]

30 **Nightingale SJ**, Hollis RP, Pepper KA, Petersen D, Yu XJ, Yang C, Bahner I, Kohn DB. Transient gene expression by nonintegrating lentiviral vectors. *Mol Ther* 2006; **13**: 1121-1132 [PMID: 16556511 DOI: 10.1016/j.ymthe.2006.01.008]

31 **Stadtfeld M**, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. *Science* 2008; **322**: 945-949 [PMID: 18818365 DOI: 10.1126/science.1162494]

32 **Guarino AT**, McKinnon RD. Reprogramming cells for brain repair. *Brain Sci* 2013; **3**: 1215-1228 [PMID: 24961526 DOI: 10.3390/brainsci3031215]

33 **Anokye-Danso F**, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 2011; **8**: 376-388 [PMID: 21474102 DOI: 10.1016/j.stem.2011.03.001]

34 **Lam AQ**, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre JV. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. *J Am Soc Nephrol* 2014; **25**: 1211-1225 [PMID: 24357672 DOI: 10.1681/ASN.2013080831]

35 **Araoka T**, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K. Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. *PLoS One* 2014; **9**: e84881 [PMID: 24454758 DOI: 10.1371/journal.pone.0084881]

36 **Inoue H**, Yamanaka S. The use of induced pluripotent stem cells in drug development. *Clin Pharmacol Ther* 2011; **89**: 655-661 [PMID: 21430656 DOI: 10.1038/clpt.2011.38]

37 **Mastri M**, Lin H, Lee T. Enhancing the efficacy of mesenchymal stem cell therapy. *World J Stem Cells* 2014; **6**: 82-93 [PMID: 24772236 DOI: 10.4252/wjsc.v6.i2.82]

38. **Ng TK**, Fortino VR, Pelaez D, Cheung HS. Progress of mesenchymal stem cell therapy for neural and retinal diseases. *World J Stem Cells* 2014; **26**: 111-119 [PMID: 24772238 DOI: 10.4252/wjsc.v6.i2.111]

39 **Gerlach GF**, Wingert RA. Kidney organogenesis in the zebrafish: insights into vertebrate nephrogenesis and regeneration. *Wiley Interdiscip Rev Dev Biol* ; **2**: 559-585 [PMID: 24014448 DOI: 10.1002/wdev.92]

40 **Poureetezadi SJ**, Wingert RA. Congenital and Acute Kidney Disease: Translational Research Insights from Zebrafish Chemical Genetics. *Gen Med (Los Angel)* 2013; **1**: 112 [PMID: 24653992 DOI: 10.4172/2327-5146.1000112]

41 **Kroeger Jr PT**, Wingert RA. Using zebrafish to study podocyte genesis during kidney development and regeneration. *Genesis* 2014 [PMID: 24920186 DOI: 10.1002/dvg.22798]

42 **McCampbell KK**, Wingert RA. New tides: using zebrafish to study renal regeneration. *Transl Res* 2014; **163**: 109-122 [PMID: 24183931 DOI: 10.1016/j.trsl.2013.10.003]

43 **Li Y**, Cheng CN, Verdun VA, Wingert RA. Zebrafish nephrogenesis is regulated by interactions between retinoic acid, mecom, and Notch signaling. *Dev Biol* 2014; **386**: 111-122 [PMID: 24309209 DOI: 10.1016/j.ydbio.2013.11.021]

44 **Diep CQ**, Ma D, Deo RC, Holm TM, Naylor RW, Arora N, Wingert RA, Bollig F, Djordjevic G, Lichman B, Zhu H, Ikenaga T, Ono F, Englert C, Cowan CA, Hukriede NA, Handin RI, Davidson AJ. Identification of adult nephron progenitors capable of kidney regeneration in zebrafish. *Nature* 2011; **470**: 95-100 [PMID: 21270795 DOI: 10.1038/nature09669]

45 **Johnson CS**, Holzemer NF, Wingert RA. Laser ablation of the zebrafish pronephros to study renal epithelial regeneration. *J Vis Exp* 2011; **54**: e2845 [PMID: 21897358 DOI: 10.3791/2845]

46 **Caine ST**, Mclaughlin KA. Regeneration of functional pronephric proximal tubules after partial nephrectomy in Xenopus laevis. *Dev Dyn* 2013; **242**: 219-229 [PMID: 23233460 DOI: 10.1002/dvdy.23916]

47 **Boualia SK**, Gaitan Y, Tremblay M, Sharma R, Cardin J, Kania A, Bouchard M. A core transcriptional network composed of Pax2/8, Gata3 and Lim1 regulates key players of pro/mesonephros morphogenesis. *Dev Biol* 2013; **382**: 555-566 [PMID: 23920117 DOI: 10.1016/j.ydbio.2013.07.028]

48 **Forbes SJ**, Rosenthal N. Preparing the ground for tissue regeneration: from mechanism to therapy. *Nat Med* 2014; **20**: 857-869 [PMID: 25100531 DOI: 10.1038/nm.3653]

49 **Humphreys BD**, Bonventre JV. Mesenchymal stem cells in acute kidney injury. *Annu Rev Med* 2008; **59**: 311-325 [PMID: 17914926]

50 **Tögel F**, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am J Physiol Renal Physiol* 2005; **289**: F31-F42 [PMID: 15713913]

51 **Herrera MB**, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. *Int J Mol Med* 2004; **14**: 1035-1041 [PMID: 15547670]

52 **Herrera MB**, Bussolati B, Bruno S, Morando L, Mauriello-Romanazzi G, Sanavio F, Stamenkovic I, Biancone L, Camussi G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. *Kidney Int* 2007; **72**: 430-441 [PMID: 17507906]

53 **Lange C**, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, Westenfelder C. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. *Kidney Int* 2005; **68**: 1613-1617 [PMID: 16164638]

54 **Choi S**, Park M, Kim J, Hwang S, Park S, Lee Y. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. *Stem Cells Dev* 2009; **18**: 521-529 [PMID: 18647091 DOI: 10.1089/scd.2008.0097]

**P-Reviewer:** Coopman K, Yorioka N **S-Editor:** Song XX **L-Editor:** **E-Editor:**

****

**Figure 1 Renal cell reprogramming methods.** (Red) Traditional reprogramming involving the use of transcription factors or miRNAs to generate pluripotent stem cells; (Yellow) partial reprogramming with transcription factors to obtain multipotent progenitors; (Blue) directed differentiation into cells with a specific phenotype by treating induced pluripotent stem cells with small molecules. These newly reprogrammed/differentiated cells can then be used therapeutically to replace lost cell types within the injured kidney.

****

**Figure 2 Challenges faced when developing induced pluripotent stem cell-based therapies.** Many issues still have to be overcome before any effective cell therapies can be used.